

IVIEW Therapeutics was awarded SBIR Innovative Year 2 Grant by NIH's National Institute of Allergy and Infectious Diseases (NIAID)

April 11, 2019

Doylestown, Pennsylvania--IVIEW Therapeutics Inc., a clinical-stage biotechnology company focusing on topical drug development on the areas of ophthalmology, otolaryngology, and dermatology, today announced that it has been awarded a Small Business Innovation Research (SBIR) Year 2 Award of \$300,000 from National Institute of Allergy and Infectious Diseases (NIAID) at National Institutes of Health (NIH). This phase I SBIR Year 2 grant is awarded based on IVIEW's successful completion of its Year 1 project since April 1, 2018. IVIEW's project is titled "In-situ gel of Povidone Iodine/Budesonide as Sustained Nasal Drug Delivery for the Treatment of Chronic Rhinosinusitis". "If successful, this combination of a long acting broad anti-infective with an anti-inflammatory agent is likely to have a significant impact on treatment of patients with chronic rhinosinusitis (CSR)", commented by the NIH reviewers. Dr. Bo Liang, Chairman & President at IVIEW comments, "The continuation of SBIR award showed the confidence of the agency towards our innovation and project progress. In the Grant Year 2 period, we will progress quickly through pre-clinical studies and plan to file US IND in the year of 2020 to move into clinical development."

About IVIEW Therapeutics Inc.

IVIEW Therapeutics Inc. is a clinical-stage biotechnology company focusing on topical drug development on specific therapeutic areas (i.e. ophthalmology, dermatology, Otolaryngology, Gynecology). It's headquartered at Pennsylvania Biotechnology Center of Bucks County and has set up its China headquarter in Hengqin, Zhuhai City, Guangdong Province and manufacturing center in Wuhu, China for develop the products in the China market. Please visit: www.iviewtherapeutics.com for more details.